{"id":24223,"date":"2023-07-24T17:21:58","date_gmt":"2023-07-24T11:51:58","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=24223"},"modified":"2023-07-24T17:26:36","modified_gmt":"2023-07-24T11:56:36","slug":"multiple-sclerosis-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment","title":{"rendered":"Revolutionizing Multiple Sclerosis Treatment: A New Era of Therapies"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f1828fbe552\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f1828fbe552\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment\/#Navigating_the_Current_Multiple_Sclerosis_Treatment_Landscape_What_Patients_Need_to_Know\" >Navigating the Current Multiple Sclerosis Treatment Landscape: What Patients Need to Know<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment\/#Emerging_Therapies_for_Multiple_Sclerosis_Treatment_A_Promising_Outlook\" >Emerging Therapies for Multiple Sclerosis Treatment: A Promising Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment\/#Recent_Developments_in_the_Multiple_Sclerosis_Treatment_Space\" >Recent Developments in the Multiple Sclerosis Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment\/#Shaping_the_Future_of_Multiple_Sclerosis_Treatment\" >Shaping the Future of Multiple Sclerosis Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Multiple sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. Multiple sclerosis is believed to impact almost <strong>1 million<\/strong> Americans, and the disease manifests itself in a variety of ways. Because nerves are affected in different ways and exhibit a variety of symptoms, no two cases of multiple sclerosis, a disease that affects the central nervous system, are the same. Women are more likely to be diagnosed with multiple sclerosis than men, with a ratio of about 3:1.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>As per DelveInsight&#8217;s estimates, the total 7MM <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-epidemiology-forecast\"><em>prevalent cases of multiple sclerosis<\/em><\/a><em> in 2022 were approximately <\/em><strong><em>1.2 million<\/em><\/strong><em> cases. The cases are expected to increase by 2032. Assessments as per DelveInsight\u2019s analysts showed that in 2022, in the United States, out of the total cases, there were approximately <\/em><strong><em>41K<\/em><\/strong><em> cases with Clinically Isolated Syndrome, <\/em><strong><em>545K<\/em><\/strong><em> cases with Relapsing-Remitting MS (RRMS), <\/em><strong><em>92K<\/em><\/strong><em> cases with Secondary-Progressive MS (SPMS), and <\/em><strong><em>44K<\/em><\/strong><em> cases with Primary-Progressive MS (PPMS).<\/em>&nbsp;<\/p>\n<\/blockquote>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"860\" height=\"303\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142703\/Multiple-Sclerosis-Epidemiology-Insights.png\" alt=\"Multiple Sclerosis Epidemiology Insights\" class=\"wp-image-24232\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142703\/Multiple-Sclerosis-Epidemiology-Insights.png 860w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142703\/Multiple-Sclerosis-Epidemiology-Insights-300x106.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142703\/Multiple-Sclerosis-Epidemiology-Insights-150x53.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142703\/Multiple-Sclerosis-Epidemiology-Insights-768x271.png 768w\" sizes=\"(max-width: 860px) 100vw, 860px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-navigating-the-current-multiple-sclerosis-treatment-landscape-what-patients-need-to-know\"><span class=\"ez-toc-section\" id=\"Navigating_the_Current_Multiple_Sclerosis_Treatment_Landscape_What_Patients_Need_to_Know\"><\/span><strong>Navigating the Current Multiple Sclerosis Treatment Landscape: What Patients Need to Know<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>There is no cure for multiple sclerosis, although there are numerous multiple sclerosis treatment options that enhance patients\u2019 long-term outcomes. Most people will deteriorate if they do not receive multiple sclerosis treatment. The goal of <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">multiple sclerosis treatment<\/a> is to decrease relapses and enhance and maintain functionality throughout the patient\u2019s life. Multiple sclerosis treatment consists of two components: DMT for the underlying immunological condition and therapies to relieve or change symptoms. Disease-modifying agents aim to reduce relapses and decrease progression. DMT is only licensed for treatment in relapsing forms of multiple sclerosis. Persistence was similarly poor among multiple sclerosis patients who switched DMTs, independent of therapy. Although oral DMTs were marginally more persistent than injectable DMTs, overall results show poor persistence to second-line therapy and underscore the need to improve long-term DMT persistence.<\/p>\n\n\n\n<p>Last year in December,&nbsp; <strong>TG Therapeutics\u2019 BRIUMVI <\/strong>has been approved by the FDA for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Approval for this indication was granted based on data from the <strong>ULTIMATE I &amp; II Phase III trials<\/strong>, which demonstrated that it was superior to teriflunomide in significantly lowering the annualized relapse rate (ARR, the primary endpoint), the number of T1 Gd-enhancing lesions, and the number of new or enlarging T2 lesions. The results of the ULTIMATE I and II trials were published in <strong>The New England Journal of Medicine<\/strong> in August 2022.<\/p>\n\n\n\n<p><strong>Cycle Pharmaceuticals<\/strong> recently announced the launch of <strong>TASCENSO ODT<\/strong>, its first medicine for treating multiple sclerosis patients in the United States. The launch assures that <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-epidemiology-forecast\">multiple sclerosis patients<\/a> in the United States who are currently receiving <strong>GILENYA<\/strong>, or generic fingolimod, have access to appropriate patient support services in addition to the bioequivalent, non-generic, TASCENSO ODT. GILENYA patient support services are slated to be phased out on March 31, 2023. The US FDA approves ASCENSO ODT for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsing-multiple-sclerosis-rms-market\">treatment of relapsing forms of multiple sclerosis<\/a>, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older, and is available in 0.25 mg and 0.5 mg doses.<\/p>\n\n\n\n<p>Additionally, with continuous efforts in research and development, various companies are developing therapies that will change the multiple sclerosis treatment dynamics in the coming years.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/multiple-sclerosis-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics-1024x194.png\" alt=\"Multiple Sclerosis Infographics\" class=\"wp-image-24233\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142739\/Multiple-Sclerosis-Infographics.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_Therapies_for_Multiple_Sclerosis_Treatment_A_Promising_Outlook\"><\/span><strong>Emerging Therapies for Multiple Sclerosis Treatment: A Promising Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Several pharmaceutical and biotechnology companies are actively working on developing therapies for multiple sclerosis treatment. <strong>NeuroVax (Immune Response BioPharma), IMS001 (ImStem Biotechnology\/Rho), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib\/M2951 (Merck Healthcare KGaA), ATA188 (Atara Biotherapeutics), ANK-700 (Anokion SA)<\/strong>, and others, are the promising emerging therapies that are in various stages of clinical development in <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight\">multiple sclerosis pipeline<\/a>.<\/p>\n\n\n\n<p><strong>NeuroVax (Immune Response BioPharma)<\/strong> is a therapeutic TCR (T-cell receptor) peptide vaccine for secondary progressive multiple sclerosis (SPMS). In March 2020, the company initiated a Phase II\/III, multi-center, randomized, double-blind, placebo-controlled, two-arm parallel design study of NeuroVax vs. Incomplete Freund\u2019s Adjuvant (IFA) placebo with Secondary Progressive SPMS. The study is estimated to complete on March 2023, with an estimated enrollment of 200 participants. However, the company is providing no updates on the drug. The vaccine is also being studied in Phase I for pediatric multiple sclerosis. In March 2014, NeuroVax Granted Fast Track FDA Designation for SPMS.<\/p>\n\n\n\n<p><strong>Tolebrutinib<\/strong>, also known as <strong>SAR442168 <\/strong>is being developed by <strong>Sanofi<\/strong>. It is a Bruton tyrosine kinase (BTK) inhibitor, with IC50 values of 0.4 nM and 0.7 nM in Ramos B cells and HMC microglia cells, respectively. Tolebrutinib blocks the BCR-mediated activation (IC50 = 10 nM) and Fc receptor activation (IC50 = 166 and 9.6 nM for Fc\u03b5R and Fc\u03b3R, respectively) of immune cells. Tolebrutinib inhibits microglial Fc\u03b3R activation through durable occupancy of BTK, with an IC50 of 157 nM. The drug is being studied in three Phase III trials for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsing-multiple-sclerosis-rms-market\">treatment of relapsing multiple sclerosis<\/a>, PPMS, and SPMS.<\/p>\n\n\n\n<p><strong>Evobrutinib\/M2951 (Merck Healthcare KGaA)<\/strong> is an oral, highly selective inhibitor of Bruton\u2019s tyrosine kinase (BTK) in clinical development as a potential multiple sclerosis treatment. It is the first BTK inhibitor to demonstrate clinical efficacy in the largest Phase II study with follow-up beyond two years as well as demonstrate an impact on early biomarkers of chronic inflammation that correlate with disease progression. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. The drug is being studied in Phase III studies for the treatment of relapsing multiple sclerosis.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"981\" height=\"376\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142636\/Multiple-Sclerosis-Therapies-in-Pipeline.png\" alt=\"Multiple Sclerosis Therapies in Pipeline\" class=\"wp-image-24231\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142636\/Multiple-Sclerosis-Therapies-in-Pipeline.png 981w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142636\/Multiple-Sclerosis-Therapies-in-Pipeline-300x115.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142636\/Multiple-Sclerosis-Therapies-in-Pipeline-150x57.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142636\/Multiple-Sclerosis-Therapies-in-Pipeline-768x294.png 768w\" sizes=\"(max-width: 981px) 100vw, 981px\" \/><\/figure>\n\n\n\n<p><strong>CNM-Au8 (Clene Nanomedicine) <\/strong>is a concentrated, aqueous suspension of clean surfaced faceted nanocrystalline gold (Au) that acts catalytically to support various intracellular biological reactions. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical-grade water.&nbsp; In October 2019, Clene Nanomedicine, Inc., announced that the National Multiple Sclerosis Society (NMSS) had awarded the company a research grant totaling more than <strong>339,000 USD<\/strong> to support the clinical development of its nanocatalytic therapeutic, CNM-Au8, for the treatment of multiple sclerosis. The drug is currently being evaluated in Phase II studies for the treatment of&nbsp; RRMS.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Developments_in_the_Multiple_Sclerosis_Treatment_Space\"><\/span><strong>Recent Developments in the Multiple Sclerosis Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>July 2023, Synaptogenix, Inc.,<\/strong> an emerging biopharmaceutical company exploring regenerative therapies for neurodegenerative diseases, signed an agreement with Cleveland Clinic to perform a phase 1 trial of Bryostatin-1 in multiple sclerosis.<\/li>\n\n\n\n<li>In<strong> July 2023, Roche <\/strong>revealed positive findings from a late-stage study of Ocrevus (ocrelizumab) as a twice-yearly subcutaneous injection in patients with relapsing types of multiple sclerosis or primary progressive multiple sclerosis.<\/li>\n\n\n\n<li>In <strong>June 2023,<\/strong> the European Commission approved Briumvi (ublituximab) for the treatment of people with active relapse multiple sclerosis, as defined by clinical or imaging characteristics.<\/li>\n\n\n\n<li>In <strong>April 2023,<\/strong> the FDA temporarily halted clinical trials of evobrutinib, Merck KGaA\u2019s investigational BTK inhibitor for relapsing forms of multiple sclerosis.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Shaping_the_Future_of_Multiple_Sclerosis_Treatment\"><\/span><strong>Shaping the Future of Multiple Sclerosis Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future outlook of multiple sclerosis treatment holds promise for patients worldwide as advancements in medical research and technology pave the way for more effective and personalized therapies. Over the past decades, significant progress has been made in understanding the complex nature of multiple sclerosis, enabling the development of novel multiple sclerosis treatments that target the immune system and repair mechanisms of the nervous system. As we venture into the future, several key trends are expected to define the landscape of multiple sclerosis treatment.<\/p>\n\n\n\n<p>Firstly, the emergence of precision medicine is set to revolutionize multiple sclerosis treatment approaches. Genetic profiling and biomarker analysis will enable clinicians to tailor therapies to individual patients, ensuring better outcomes and minimizing side effects. Additionally, a deeper understanding of the disease\u2019s underlying mechanisms may lead to the discovery of new targets for drugs, further enhancing <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">multiple sclerosis treatment options<\/a>.<\/p>\n\n\n\n<p>Secondly, innovative therapies, including gene and cell-based therapies, hold great potential for halting or even reversing the progression of multiple sclerosis. Techniques like gene editing and stem cell transplantation have already shown promise in preclinical studies, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight\">ongoing multiple sclerosis clinical trials<\/a> are expected to shed light on their safety and efficacy in human patients.<\/p>\n\n\n\n<p>Thirdly, the integration of digital health solutions will transform the way multiple sclerosis is managed. Wearable devices and mobile applications will enable real-time monitoring of symptoms, disease progression, and treatment responses, empowering both patients and healthcare providers to make informed decisions and adjust <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">multiple sclerosis therapies<\/a> as needed.<\/p>\n\n\n\n<p>Moreover, collaborative research efforts across the globe will facilitate knowledge exchange and accelerate breakthroughs in multiple sclerosis treatment. International partnerships and data-sharing initiatives will enable researchers to pool resources and better understand the disease\u2019s complexities, fostering a more comprehensive approach to managing multiple sclerosis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1690180137605\"><strong class=\"schema-faq-question\"><strong>1. What is multiple sclerosis?<\/strong><\/strong> <p class=\"schema-faq-answer\">Multiple sclerosis is a chronic neurological disorder that affects the central nervous system. It is characterized by the immune system mistakenly attacking the protective covering of nerve fibers, known as myelin, leading to communication problems between the brain and the rest of the body.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1690180145948\"><strong class=\"schema-faq-question\"><strong>2. What are multiple sclerosis symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">The symptoms of multiple sclerosis can vary widely from person to person and depend on the location and extent of nerve damage. Some common multiple sclerosis symptoms include fatigue, difficulty walking, numbness or tingling in the limbs, muscle weakness, problems with coordination and balance, blurred or double vision, dizziness, and cognitive impairment.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1690180156031\"><strong class=\"schema-faq-question\"><strong>3. How is multiple sclerosis diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Diagnosing multiple sclerosis can be challenging as there is no specific test that can confirm the presence of the disease definitively. Instead, doctors rely on a combination of medical history, neurological examinations, and diagnostic tests.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1690180164926\"><strong class=\"schema-faq-question\"><strong>4. How is multiple sclerosis treated?<\/strong><\/strong> <p class=\"schema-faq-answer\">Although there is no known cure for multiple sclerosis, there are various treatment options available to manage the symptoms and slow down the progression of the disease. Multiple sclerosis treatment approaches typically focus on three main aspects: modifying the disease course, managing symptoms, and providing supportive care.<\/p> <\/div> <\/div>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook-1024x256.png\" alt=\"Multiple Sclerosis Market Outlook\" class=\"wp-image-24230\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142555\/Multiple-Sclerosis-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Multiple sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. Multiple sclerosis is believed to impact almost 1 million Americans, and the disease manifests itself in a variety of ways. Because nerves are affected in different ways and exhibit a variety of symptoms, no two cases of multiple sclerosis, a disease that [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":24227,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1497,20100,3330,3331,17704,17705],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-24223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-multiple-sclerosis","tag-multiple-sclerosis-drug","tag-multiple-sclerosis-epidemiology","tag-multiple-sclerosis-market","tag-multiple-sclerosis-pipeline","tag-multiple-sclerosis-treatment","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evolving Multiple Sclerosis Treatment | Recent FDA Approvals<\/title>\n<meta name=\"description\" content=\"The future of multiple sclerosis treatment holds promise as advancements in medical R&amp;D pave way for effective and personalized therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evolving Multiple Sclerosis Treatment | Recent FDA Approvals\" \/>\n<meta property=\"og:description\" content=\"The future of multiple sclerosis treatment holds promise as advancements in medical R&amp;D pave way for effective and personalized therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-24T11:51:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-24T11:56:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142404\/multiple-sclerosis-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evolving Multiple Sclerosis Treatment | Recent FDA Approvals","description":"The future of multiple sclerosis treatment holds promise as advancements in medical R&D pave way for effective and personalized therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment","og_locale":"en_US","og_type":"article","og_title":"Evolving Multiple Sclerosis Treatment | Recent FDA Approvals","og_description":"The future of multiple sclerosis treatment holds promise as advancements in medical R&D pave way for effective and personalized therapies.","og_url":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-07-24T11:51:58+00:00","article_modified_time":"2023-07-24T11:56:36+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142404\/multiple-sclerosis-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment","url":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment","name":"Evolving Multiple Sclerosis Treatment | Recent FDA Approvals","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142404\/multiple-sclerosis-treatment.png","datePublished":"2023-07-24T11:51:58+00:00","dateModified":"2023-07-24T11:56:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The future of multiple sclerosis treatment holds promise as advancements in medical R&D pave way for effective and personalized therapies.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180137605"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180145948"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180156031"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180164926"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142404\/multiple-sclerosis-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142404\/multiple-sclerosis-treatment.png","width":1200,"height":800,"caption":"multiple-sclerosis-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180137605","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180137605","name":"1. What is multiple sclerosis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Multiple sclerosis is a chronic neurological disorder that affects the central nervous system. It is characterized by the immune system mistakenly attacking the protective covering of nerve fibers, known as myelin, leading to communication problems between the brain and the rest of the body.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180145948","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180145948","name":"2. What are multiple sclerosis symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The symptoms of multiple sclerosis can vary widely from person to person and depend on the location and extent of nerve damage. Some common multiple sclerosis symptoms include fatigue, difficulty walking, numbness or tingling in the limbs, muscle weakness, problems with coordination and balance, blurred or double vision, dizziness, and cognitive impairment.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180156031","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180156031","name":"3. How is multiple sclerosis diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Diagnosing multiple sclerosis can be challenging as there is no specific test that can confirm the presence of the disease definitively. Instead, doctors rely on a combination of medical history, neurological examinations, and diagnostic tests.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180164926","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-sclerosis-treatment#faq-question-1690180164926","name":"4. How is multiple sclerosis treated?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Although there is no known cure for multiple sclerosis, there are various treatment options available to manage the symptoms and slow down the progression of the disease. Multiple sclerosis treatment approaches typically focus on three main aspects: modifying the disease course, managing symptoms, and providing supportive care.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/24142404\/multiple-sclerosis-treatment-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Multiple Sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis Drug<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jul 24, 2023","modified":"Updated on Jul 24, 2023"},"absolute_dates_time":{"created":"Posted on Jul 24, 2023 5:21 pm","modified":"Updated on Jul 24, 2023 5:26 pm"},"featured_img_caption":"multiple-sclerosis-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=24223"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24223\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/24227"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=24223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=24223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=24223"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=24223"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=24223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}